Phase 1/2 study of oral MKC-1 administered twice daily for 14 consecutive days every 3 weeks in combination with pemetrexed.

Trial Profile

Phase 1/2 study of oral MKC-1 administered twice daily for 14 consecutive days every 3 weeks in combination with pemetrexed.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Oct 2014

At a glance

  • Drugs MKC 1 (Primary) ; Pemetrexed
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors EntreMed
  • Most Recent Events

    • 19 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Nov 2008 Primary endpoint, tumour response, met for the efficacy portion of the trial according to an EntreMed media release.
    • 23 Oct 2008 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top